For Facebook (Terri) ECTRIMS PARTIAL

ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity

ECTRIMS Congress 2013: African Americans With MS at More Visual Risk

ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS

Halting MS to Be Focus at ECTRIMS Congress 2013 

 ECTRIMS Congress 2013:  New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS

ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES? 

ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -

 ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems

ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate)  20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress

ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE

ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH

  

ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM" (Day 1 ECTRIMS News)

ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)

ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?

  

ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -

ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients